Natco Pharma has reported a total income of Rs.427.3 crores during the period ended June 30, 2021,  as compared to Rs 582.1 crores in the period ended June 30, 2020. The total income for the period ended March 31, 2021, stood at Rs 359.7 crores.

The company has posted a net profit of Rs.75 crores for the period ended June 30, 2021, as against a net profit of Rs 122.8 crores for the period ended June 30, 2020. For the period ended March 31, 2021, the profit stood at Rs 53 crores.

The company has reported EPS of Rs.4.11 for the period ended June 30, 2021, as compared to Rs 6.73 for the period ended June 30, 2020. The EPS for the period ended March 31, 2021, stood at Rs.2.90.

The degrowth in sales can be partially attributed to the higher proportion of the initial phase of pandemic exports to the USA in Chloroquine Phosphate tablets and Oseltamivir Phosphate capsules in the revenues for the quarter ended 30th June 2020, the company said in a statement.

The pandemic continues to impact the revenues of the company but recovered compared to the quarter ending March 2021. The company has strong product launches both in export markets and domestic India business during the current financial year and expects to have good growth, the statement added.

The Board of Directors has recommended an interim dividend of INR 2.0 per equity share of INR 2.0 each, during the First Quarter of FY 2021-22.